FCM
Farallon Capital Management Portfolio holdings
AUM
$17.7B
1-Year Est. Return
25.69%
1 Year Est. Return
+25.69%
AUM
$21.8B
AUM Growth
+$3.52B
(+19%)
Holding
163
Top Buys
| 1 | +$3.4B | |
| 2 | +$666M | |
| 3 | +$223M | |
| 4 |
Thermo Fisher Scientific
TMO
|
+$141M |
| 5 |
AZEK
The AZEK Co
AZEK
|
+$109M |
Top Sells
| 1 | +$816M | |
| 2 | +$403M | |
| 3 | +$286M | |
| 4 |
Microsoft
MSFT
|
+$268M |
| 5 |
Intuit
INTU
|
+$239M |
Sector Composition
| 1 | Healthcare | 35.61% |
| 2 | Technology | 14.22% |
| 3 | Financials | 9.81% |
| 4 | Communication Services | 7.87% |
| 5 | Industrials | 5.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Silicon Motion
SIMO
$3.08B
| – | – |
-29,298
|
|
||
152
Sarepta Therapeutics
SRPT
$2.39B
| – | – |
-2,341,424
|
|
||
153
Transmedics
TMDX
$4.74B
| – | – |
-3,000
|
|
||
|
X
154
DELISTED
US Steel
X
| – | – |
-2,135,000
|
|
||
155
Zymeworks
ZYME
$1.99B
| – | – |
-400,000
|
|
||
|
SGI
156
Somnigroup International
SGI
$18.9B
| – | – |
-1,326,242
|
|
||
|
GATE
157
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
| – | – |
-150,000
|
|
||
|
ITCI
158
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-3,055,000
|
|
||
159
Chemed
CHE
$5.99B
| – | – |
-400
|
|
||
160
Biohaven
BHVN
$1.28B
| – | – |
-4,813,167
|
|
||
|
BPMC
161
DELISTED
Blueprint Medicines
BPMC
| – | – |
-4,000
|
|
||
|
GATEW
162
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
| – | – |
-1,485,000
|
|